Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (926) Arrow Down
Filter Results: (926) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (926)
    • People  (2)
    • News  (70)
    • Research  (779)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (668)

Show Results For

  • All HBS Web  (926)
    • People  (2)
    • News  (70)
    • Research  (779)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (668)
← Page 37 of 926 Results →
  • June 2014
  • Supplement

Merrimack Pharmaceuticals, Inc. (B)

By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
  • August 1994
  • Teaching Note

Nippon Kayaku TN

By: Robin Cooper and Robert S. Kaplan
Keywords: Pharmaceutical Industry; Pharmaceutical Industry; Tokyo
Citation
Related
Cooper, Robin, and Robert S. Kaplan. "Nippon Kayaku TN." Harvard Business School Teaching Note 195-069, August 1994.
  • February 2010 (Revised April 2010)
  • Case

Organization and Strategy at Millennium (A)

By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
  • January 2009
  • Teaching Note

Biocon: Launching a New Cancer Drug in India (TN)

By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
Keywords: Product Launch; Market Timing; Price; Distribution Channels; Marketing Strategy; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry; India
Citation
Purchase
Related
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India (TN)." Harvard Business School Teaching Note 509-039, January 2009.
  • August 2007 (Revised November 2008)
  • Case

Biocon: Launching a New Cancer Drug in India

By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Biotechnology Industry; India
Citation
Educators
Purchase
Related
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
  • March 2006
  • Teaching Note

Stan Lapidus: Profile of a Medical Entrepreneur (TN)

By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
Keywords: Personal Development and Career; Entrepreneurship; Business Startups; Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Higgins, Robert F., Richard G. Hamermesh, and Erin Seefeld. "Stan Lapidus: Profile of a Medical Entrepreneur (TN)." Harvard Business School Teaching Note 806-149, March 2006.
  • April 2003 (Revised October 2004)
  • Case

Novartis: The Challenge of Success (B)

By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
  • April 2003 (Revised October 2004)
  • Case

Novartis: The Challenge of Success (A)

By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
  • December 2002
  • Teaching Note

Abgenix and the XenoMouse (TN)

By: John T. Gourville
Teaching Note for (501-061). View Details
Keywords: Health Testing and Trials; Decision Choices and Conditions; Sales; Product Development; Joint Ventures; Health Industry; Health Industry
Citation
Purchase
Related
Gourville, John T. "Abgenix and the XenoMouse (TN)." Harvard Business School Teaching Note 503-046, December 2002.
  • May 2002 (Revised December 2003)
  • Teaching Note

Medicines Company, The TN

By: John T. Gourville
Teaching Note for (9-502-006). View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry
Citation
Purchase
Related
Gourville, John T. "Medicines Company, The TN." Harvard Business School Teaching Note 502-076, May 2002. (Revised December 2003.)
  • August 2001 (Revised March 2008)
  • Case

Helios Health (A)

By: Regina E. Herzlinger and Alfred Martin
Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service? View Details
Keywords: Entrepreneurship; Price; Health Care and Treatment; Information Publishing; Innovation and Invention; Product Marketing; Demand and Consumers; Health Industry; Health Industry
Citation
Find at Harvard
Related
Herzlinger, Regina E., and Alfred Martin. "Helios Health (A)." Harvard Business School Case 302-022, August 2001. (Revised March 2008.)
  • March 1995 (Revised January 1996)
  • Teaching Note

Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN

By: David J. Collis
Teaching Note for (9-795-040). View Details
Keywords: Chemical Industry; Chemical Industry; Switzerland
Citation
Purchase
Related
Collis, David J. "Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN." Harvard Business School Teaching Note 795-107, March 1995. (Revised January 1996.)
  • 2007
  • Chapter

Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business

By: Rohit Deshpandé and Zoe Chance
Keywords: Health Disorders; Poverty; Product Marketing; Customers; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Related
Deshpandé, Rohit, and Zoe Chance. "Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business." In Business Solutions for the Global Poor: Creating Social and Economic Value, edited by V. Kasturi Rangan, John A. Quelch, Gustavo Herrero, and Brooke Barton. John Wiley & Sons, 2007.
  • September 1990 (Revised March 1991)
  • Supplement

RU 486 (B)

By: Joseph L. Badaracco Jr.
Describes how Roussel UCLAF resolved the dilemma. Intended for use as an in-class handout. View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States
Citation
Purchase
Related
Badaracco, Joseph L., Jr. "RU 486 (B)." Harvard Business School Supplement 391-051, September 1990. (Revised March 1991.)
  • 15 Dec 2014
  • Research & Ideas

Deconstructing the Price Tag

expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that... View Details
Keywords: by Dina Gerdeman; Retail
  • 17 Jun 2002
  • Research & Ideas

Entrepreneurship in Asia and Foreign Direct Investment

complicated organizational know-how, such as the pharmaceutical and electronics industries.) "The FDI that I'm looking at also has gone into industries in which the local entrepreneurs in these... View Details
Keywords: by Martha Lagace
  • 08 Jul 2021
  • Blog Post

Managing Sustainable Advantage with Key ESG Co-Founders, Anne-Marie Schoonbeek and Heleen van Poecke

internship and then later back to McKinsey after graduation, where she focused on both large-cap and startups in the pharmaceuticals and biotech space. “For me, this was a way of making an impact,” said Schoonbeek. van Poecke began her... View Details
Keywords: Entrepreneurship; Technology
  • 22 Apr 2014
  • First Look

First Look: April 22

occurred in the pharmaceutical industry over the past two decades. Since 1989, a number of major pharmaceutical companies (Merck, Novartis, Pfizer, etc.) have chosen to locate... View Details
Keywords: Sean Silverthorne
  • April 2024 (Revised November 2024)
  • Case

Moderna: Pioneering a People Platform to Accelerate Science Innovation

By: Tatiana Sandino, Emil Dy and Samuel Grad
Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details
Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Sandino, Tatiana, Emil Dy, and Samuel Grad. "Moderna: Pioneering a People Platform to Accelerate Science Innovation." Harvard Business School Case 124-091, April 2024. (Revised November 2024.)
  • November 2020
  • Teaching Note

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
Keywords: Mergers and Acquisitions; Valuation; Value; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Teaching Note 221-036, November 2020.
  • ←
  • 37
  • 38
  • …
  • 46
  • 47
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.